Abstract
Dystonia is a hyperkinetic disabling movement disorder. In the dtsz hamster, a model of paroxysmal dystonia, pronounced antidystonic effects of the KV7.2-5 potassium channel opener retigabine and aggravation of dystonia by a selective KV7.2-5 blocker indicated a pathophysiological role of an abnormal expression of KV7 channels. We therefore investigated the expression of KV7 subunits in brains of dystonic hamsters. While KV7.2 and KV7.3 subunits were unaltered, lower KV7.5 mRNA levels became evident in motor areas and in limbic structures of dystonic hamsters. The KV7.2/3 subunit-preferring channel opener N-(6-chloropyridin-3-yl)-3,4- difluorobenzamide (ICA 27243; 10-30 mg/kg i.p.) failed to reduce the severity of dystonia in mutant hamsters, suggesting that the previously observed antidystonic action of retigabine is mediated by the activation of KV7.5 channels. The experiments indicate a functional relevance for KV7.5 channels in paroxysmal dystonia. We suggest that compounds highly selective for subtypes of KV7 channels, i.e. for KV7.5, may provide new therapeutic approaches.
Keywords: animal model, dyskinesia, dystonia, ICA 27243, KCNQ, voltage-gated potassium channels.
CNS & Neurological Disorders - Drug Targets
Title:Lower KV7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
Volume: 15 Issue: 1
Author(s): Svenja E. Sander, Mustansir Diwan, Roger Raymond, José N Nobrega and Angelika Richter
Affiliation:
Keywords: animal model, dyskinesia, dystonia, ICA 27243, KCNQ, voltage-gated potassium channels.
Abstract: Dystonia is a hyperkinetic disabling movement disorder. In the dtsz hamster, a model of paroxysmal dystonia, pronounced antidystonic effects of the KV7.2-5 potassium channel opener retigabine and aggravation of dystonia by a selective KV7.2-5 blocker indicated a pathophysiological role of an abnormal expression of KV7 channels. We therefore investigated the expression of KV7 subunits in brains of dystonic hamsters. While KV7.2 and KV7.3 subunits were unaltered, lower KV7.5 mRNA levels became evident in motor areas and in limbic structures of dystonic hamsters. The KV7.2/3 subunit-preferring channel opener N-(6-chloropyridin-3-yl)-3,4- difluorobenzamide (ICA 27243; 10-30 mg/kg i.p.) failed to reduce the severity of dystonia in mutant hamsters, suggesting that the previously observed antidystonic action of retigabine is mediated by the activation of KV7.5 channels. The experiments indicate a functional relevance for KV7.5 channels in paroxysmal dystonia. We suggest that compounds highly selective for subtypes of KV7 channels, i.e. for KV7.5, may provide new therapeutic approaches.
Export Options
About this article
Cite this article as:
Sander E. Svenja, Diwan Mustansir, Raymond Roger, Nobrega N José and Richter Angelika, Lower KV7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia, CNS & Neurological Disorders - Drug Targets 2016; 15 (1) . https://dx.doi.org/10.2174/1871527315666151110124136
DOI https://dx.doi.org/10.2174/1871527315666151110124136 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Red Cell Membrane Lipids in Hemoglobinopathies
Current Molecular Medicine Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Recognition-induced Conformational Changes in Protein-Protein Docking
Current Pharmaceutical Biotechnology Age-related Differences in Mu Rhythm During Emotional Destination Memory Task
Current Aging Science Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors
Current Cancer Drug Targets Oxidative Stress, Mitochondrial Dysfunction, and Stress Signaling in Alzheimers Disease
Current Alzheimer Research Hydrophilic Dual Vitamin E-Like Antioxidants as Modulators of Inflammatory Response in Low-Flow States and Impaired Wound Healing
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances and Applications in Synchrotron X-Ray Protein Footprinting for Protein Structure and Dynamics Elucidation
Protein & Peptide Letters Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design Methods for Detection of Handwriting/Drawing Impairment Using Inputs from Touch Screens
Recent Patents on Signal Processing (Discontinued) Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Biomarkers of Osteoarthritis: A Review of Recent Research Progress on Soluble Biochemical Markers, Published Patents and Areas for Future Development
Recent Patents on Biomarkers Alzheimers Disease - An Interactive Perspective
Current Alzheimer Research Pathogens and Chronic or Long-Term Neurologic Disorders
Cardiovascular & Hematological Disorders-Drug Targets The Effect of Cannabis on Perception of Time: A Critical Review
Current Pharmaceutical Design